Mycobacterium bovis BCG: Close to Reach an End to the Puzzle

Abstract

The vaccine M. bovis BCG is the most applied worldwide nevertheless, it is protective efficacy especially against pulmonary tuberculosis is very variable. Diverse investigations are carried out to improve by recombinant BCG or to a new prototype vaccine. Neither, candidates for vaccines have increased the protection that confers the current BCG vaccine. While preclinical essays are realized with the most recent BCG vaccines. Although there is not sufficient knowledge based on recent discovery processes of biological such as, RNA that plays a very important role in the interaction cell host-M. bovis BCG over some, provide many answers that we are no aware, regarding to the protection against tuberculosis due to BCG vaccination.